Related Experiment Videos
[Diethylstilbestrol-induced liver cancer?]
Schweizerische Medizinische Wochenschrift
|July 25, 1981
Summary
This case study examines a 77-year-old man who developed hepatocellular carcinoma without cirrhosis after 12 years of diethylstilbestrol treatment for prostate cancer. The study explores the potential link between this hormonal therapy and the development of liver cancer.
Area of Science:
- Oncology
- Hepatology
- Endocrinology
Background:
- Diethylstilbestrol (DES) is a synthetic estrogen previously used for various medical conditions.
- Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer.
- Cirrhosis is a frequent precursor to HCC, but HCC can also arise in non-cirrhotic livers.
Observation:
- A 77-year-old male patient presented with hepatocellular carcinoma.
- The patient had no underlying cirrhosis.
- He received a cumulative dose of 668g of diethylstilbestrol over 12 years for suspected prostate carcinoma.
Findings:
- The development of HCC in a non-cirrhotic liver.
- The prolonged exposure to diethylstilbestrol as a potential contributing factor.
Implications:
- This case raises concerns about the potential hepatocarcinogenicity of diethylstilbestrol, even in the absence of cirrhosis.
- Highlights the importance of considering iatrogenic factors in cancer development.
- Suggests further investigation into the mechanisms linking synthetic estrogens to liver cancer.